These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27882801)

  • 1. Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study.
    Stuurman AL; Verstraeten T; De Schryver A
    Expert Rev Vaccines; 2017 Feb; 16(2):187-191. PubMed ID: 27882801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine.
    Demeulemeester M; Lavis N; Balthazar Y; Lechien P; Heijmans S
    Hum Vaccin Immunother; 2017 Apr; 13(4):889-894. PubMed ID: 27960593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season.
    Dos Santos G; Nguyen BY; Damaso S; Godderis L; Martínez-Gómez X; Eckermann T; Loos H; Salamanca de la Cueva I; Shende V; Schmidt AC; Yeakey A
    Drug Saf; 2020 Mar; 43(3):265-279. PubMed ID: 31884676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England.
    de Lusignan S; Dos Santos G; Correa A; Haguinet F; Yonova I; Lair F; Byford R; Ferreira F; Stuttard K; Chan T
    BMJ Open; 2017 May; 7(5):e015469. PubMed ID: 28515198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis.
    de Lusignan S; Dos Santos G; Byford R; Schuind A; Damaso S; Shende V; McGee C; Yonova I; Ferreira F
    Adv Ther; 2018 Aug; 35(8):1199-1214. PubMed ID: 29995300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis.
    Dos Santos G; Shende V; Damaso S; Yeakey A
    Adv Ther; 2019 Dec; 36(12):3340-3355. PubMed ID: 31595482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of text-messaging to voice telephone interviews for active surveillance of adverse events following immunisation.
    Regan AK; Blyth CC; Tracey L; Mak DB; Richmond PC; Effler PV
    Vaccine; 2015 Jul; 33(31):3689-94. PubMed ID: 26079616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network.
    Bettinger JA; De Serres G; Valiquette L; Vanderkooi OG; Kellner JD; Coleman BL; Top KA; Isenor JE; McCarthy AE;
    Euro Surveill; 2020 Jun; 25(22):. PubMed ID: 32524947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia.
    Regan AK; Tracey L; Gibbs R
    Vaccine; 2015 Nov; 33(46):6149-51. PubMed ID: 26476362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16.
    Bricout H; Chabanon AL; Souverain A; Sadorge C; Vesikari T; Caroe TD
    Euro Surveill; 2017 May; 22(18):. PubMed ID: 28494843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia.
    Clothier HJ; Crawford N; Russell MA; Buttery JP
    Euro Surveill; 2017 May; 22(20):. PubMed ID: 28552101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid assessment of enhanced safety surveillance for influenza vaccine.
    Alguacil-Ramos AM; Portero-Alonso A; Pastor-Villalba E; Muelas-Tirado J; Díez-Domingo J; Sanchis-Ferrer A; Lluch-Rodrigo JA
    Public Health; 2019 Mar; 168():137-141. PubMed ID: 30769245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of a cell culture derived trivalent subunit inactivated influenza vaccine administered to healthy children and adolescents: A Phase III, randomized, multicenter, observer-blind study.
    Nolan T; Chotpitayasunondh T; Capeding MR; Carson S; Senders SD; Jaehnig P; de Rooij R; Chandra R
    Vaccine; 2016 Jan; 34(2):230-236. PubMed ID: 26643931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
    J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of the feasibility and usability of a proof of concept mobile app for adverse event reporting post influenza vaccination.
    Wilson K; Atkinson KM; Westeinde J; Bell C; Marty K; Fergusson D; Deeks SL; Crowcroft N; Bettinger JA
    Hum Vaccin Immunother; 2016 Jul; 12(7):1738-48. PubMed ID: 26905396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers.
    Coleman BL; McNeil SA; Langley JM; Halperin SA; McGeer AJ
    Vaccine; 2015 Nov; 33(48):6635-40. PubMed ID: 26529074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.
    Halsey NA; Griffioen M; Dreskin SC; Dekker CL; Wood R; Sharma D; Jones JF; LaRussa PS; Garner J; Berger M; Proveaux T; Vellozzi C; ; Broder K; Setse R; Pahud B; Hrncir D; Choi H; Sparks R; Williams SE; Engler RJ; Gidudu J; Baxter R; Klein N; Edwards K; Cano M; Kelso JM
    Vaccine; 2013 Dec; 31(51):6107-12. PubMed ID: 24120547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.